Target intelligence / Profile preview

Metalloendopeptidase OMA1, mitochondrial (OMA1)

Target
OMA1
Molecular classification
Enzyme, Metalloendopeptidase, Mitochondrial protease
01

Overview

Metalloendopeptidase OMA1, mitochondrial (abbreviation: OMA1), is a Zn-dependent metalloprotease located in the inner mitochondrial membrane[1][9]. It is part of the mitochondrial quality control system and is activated in response to diverse mitochondrial stresses, including loss of membrane potential and oxidative damage, where it cleaves several substrates such as the dynamin-like GTPase OPA1 and the stress signaling protein DELE1[1][2]. OMA1-mediated OPA1 cleavage is associated with mitochondrial fragmentation and the initiation of apoptosis[1]. OMA1 activation is important for adaptive stress response, prevention of reactive oxygen species accumulation, and maintenance of mitochondrial function[2]. Dysfunction or aberrant regulation of OMA1 has been associated with neurodegeneration, heart failure, cancer, and other metabolic and degenerative diseases, mostly through its influence on OPA1 and DELE1 but also possibly by other mechanisms[1]. There are currently no drugs or established biomarkers directly targeting OMA1, and its manipulation poses potential safety concerns related to mitochondrial and cellular homeostasis[1][2].

Other names
OMA1 zinc metallopeptidaseOMA1 proteaseOMA1 mitochondrialOMA1OMA1 gene product
02

Mechanism of action

Proteolytic cleavage of OPA1 and DELE1 in response to mitochondrial stress, triggers apoptosis or integrated stress response; general stress-activated mitochondrial quality control

03

Biological functions

Mitochondrial quality controlStress responseRegulation of mitochondrial dynamicsApoptosisProteolytic cleavage of inner membrane proteins
04

Disease associations

Neurodegenerative diseaseCardiovascular diseaseCancerAmyotrophic lateral sclerosis (ALS, suggested involvement)Parkinson's disease (via degradation of PINK1 mutants)Other (general metabolic diseases, energy regulation)
05

Safety considerations

Potential impact on mitochondrial homeostasis and energy metabolism if targeted pharmacologicallyloss of function leads to heightened oxidative stress sensitivity and metabolic alterations[2][1]

Beyond the preview

Go deeper on Metalloendopeptidase OMA1, mitochondrial (OMA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metalloendopeptidase OMA1, mitochondrial (OMA1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call